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Obesity and its metabolic complications have emerged as the epidemic of the new
millennia. The use of obese rodent models continues to be a productive component
of efforts to understand the concomitant metabolic complications of this disease. In
1978, the JCR:LA-cp rat model was developed with an autosomal recessive corpulent
(cp) trait resulting from a premature stop codon in the extracellular domain of the leptin
receptor. Rats that are heterozygous for the cp trait are lean-prone, while those that are
homozygous (cp/cp) spontaneously display the pathophysiology of obesity as well as a
metabolic syndrome (MetS)-like phenotype. Over the years, there have been formidable
scientific contributions that have originated from this rat model, much of which has been
reviewed extensively up to 2008. The premise of these earlier studies focused on characterizing the pathophysiology of MetS-like phenotype that was spontaneously apparent
in this model. The purpose of this review is to highlight areas of recent advancement
made possible by this model including; emerging appreciation of the “thrifty gene”
hypothesis in the context of obesity, the concept of how chronic inflammation may drive
obesogenesis, the impact of acute forms of inflammation to the brain and periphery
during chronic obesity, the role of dysfunctional insulin metabolism on lipid metabolism
and vascular damage, and the mechanistic basis for altered vascular function as well as
novel parallels between the human condition and the female JCR:LA-cp rat as a model
for polycystic ovary disease (PCOS).
Keywords: obesity, thrifty genotype, metabolic syndrome, immune function, inflammation, cardiovascular
diseases, pcos, JCR rat

INTRODUCTION
Obesity and the Clinical Problem for Our Generation

Obesity and its metabolic complications have emerged as the epidemic of the new millennia.
Fueled by a caloric-dense (and nutrient-poor) food chain that is readily available in most developed
countries, the current generation reflects the expression of a human phenotype plagued by the
“obesogenic” environment. We have become so efficient at creating foods that target brain reward
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pathways to stimulate addictiveness and palatability, that we now
suffer from the health consequences of not being able to alter our
behavior away from this food environment. So too, we are just as
guiltily of bestowing this new found talent on the next generation
of young adults.
For many scientists, this problem has become a life-long commitment to understand how overnutrition and nutrient-poor
choices on the backdrop of the existing food chain could result in
such a devastating change to our metabolic prognosis in such a
short period of time. Animal models have been a prominent tool
in this endeavor. One such model, the JCR:LA-cp rat (re-derived
in Edmonton, AB, Canada in 1978 by Dr. James C. Russell), has
received significant attention. For the last three decades, this
model has appeared in the literature every year, often in numerous forms spanning facets of nutrition, endocrinology, metabolic
syndrome (MetS), obesity, lipid metabolism, vascular myocardial
pathophysiology, and pharmacology (Figure 1).

at the University of Alberta. These rats were the founders of a
colony that retained ~3% of the genome derived from the obese
spontaneously hypertensive rat (or SHROB). Unlike other NIH
colonies, at the time, that were maintained inbred and congenic,
the JCR:LA-cp strain has been maintained as a closed outbred
colony at the University of Alberta to retain the unknown genetic
elements leading to early development of cardiovascular disease
(CVD).
The formidable contributions that have originated from this
rat model have been well documented and reviewed extensively
up to 2008 (1–3). The premise of the early studies focused on
characterizing the pathophysiology of MetS-like phenotype that
was spontaneously apparent in this model. Highlights of the work
from this period included useful descriptions of the biochemical profile, careful reports of glucose and insulin metabolism,
endothelial function and its impairment, and unique observations of early vascular atherogenesis.

The JCR:LA-cp Rat

Contributions of the JCR:LA-cp Rat and
Recent Advancements

In 1978, at the fifth backcross to the LA/N strain [including
elements of the corpulent (cp) trait], initial breeding stock was
sent from National Institutes of Health (NIH) by Dr. Carl T.
Hanson to the laboratory of one of the authors (James C. Russell)

The purpose of this review is to celebrate the major contributions
that this rat model has served over many years and to highlight
recent advancements. In a unique way, this model has been

FIGURE 1 | The JCR:LA-cp rat: useful animal model for studies of metabolic syndrome and mechanisms of associated comorbidities.
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carefully studied, yet successfully pervasive into the broad areas
of research that underpin our understanding of obesity and the
MetS.
We wish to highlight areas of advancement made possible
by this model including; emerging appreciation of the “thrifty
gene” hypothesis in the context of obesity, the concept of how
chronic inflammation may drive obesogenesis, the impact of
acute forms of inflammation to the brain and periphery during
chronic obesity, the role of dysfunctional insulin metabolism on
lipid metabolism and vascular damage, the mechanistic basis for
altered vascular function as well as novel parallels between the
human condition and the female JCR:LA-cp rat as a model for
polycystic ovary disease (PCOS).

(35–40 days) male JCR:LA-cp rats (obese-prone and lean-prone)
were exposed to 1.5 h/day of feeding and 22.5 h/day of voluntary
wheel running (14). We have shown that this experimental design
leads to increased wheel running or food-seeking behavior and
self-starvation (14). Initial body weights were similar in both
groups of animals; however, the obese-prone animals survived
twice as long (8.2 ± 1.1 vs. 3.5 ± 0.2 days) and ran similarly, compared to their lean-prone counterparts (14). A follow-up study
showed that prior conditioning with dietary energy restriction
for 1 week provided a survival advantage to the obese-prone
JCR:LA-cp phenotype (15). Dietary energy restriction primed
the animals to regulate energy homeostasis pathways following
exposure to continued energy restriction and food-seekingrelated activity (15). The obese- and lean-prone phenotypes have
metabolic differences, which we have shown are associated with
alterations in feeding-related neuropeptide gene expression in the
arcuate nucleus of the hypothalamus including NPY, Orexin A,
CART, and POMC. In addition, hypothalmic pro-inflammatory
cytokines and oxidative stress markers IL-6, Tnf-α, and NF-kβ,
superoxide dismutase-1 (SOD1), glutathione reductase (GRx),
glutathione peroxidase (GPx), and catalase mRNA are elevated
in the obese-prone phenotype (16). Interestingly, when the
obese- and lean-prone animals are exposed to the same degree
of dietary energy restriction, these hypothalamic inflammatory
and oxidative stress markers were improved in the obese-prone
phenotype, while they are exacerbated in the lean-prone phenotype (16). These findings demonstrate that, in juvenile JCR:LA-cp
rodents, the metabolic and neural adaptation to energy restriction
are dependent on the phenotype, and this can confer a survival
advantage (16). Overall, our research findings suggest that obesity
is a developmental outcome dependent on the interrelationship
of an obese-prone genotype and feeding conditions/“obesogenic”
environment. The JCR:LA-cp rodent offers a unique opportunity
to study the underlying mechanisms of the behavioral and physiological pathways involved in the development of obesity and the
possible conference of evolutionary survival traits.

OBESITY: TESTING THE “THRIFTY GENE”
HYPOTHESIS OF ADAPTATION TO
DIETARY ENERGY INTAKE
The prevalence of obesity is continuing to increase at an alarming
rate in both economically advanced Western societies and developing countries in economic–nutrition transition (4). Obesity
is linked to adverse short-term and long-term health outcomes,
including increased risk of CVD and insulin resistance leading to
overt type 2 diabetes (T2D) (5, 6). Genetic differences between
individuals explain a major proportion of the within-population
variation in body mass index (7). However, genetic susceptibility
alone may not result in obesity without other environmental
influences (8). A positive energy balance beyond meeting energy
requirements results in excess dietary energy intake being preferentially stored as triglycerides (TG) in adipose tissue, resulting in
an increase in body weight and fat mass. Obesity can be viewed
as a result of physiological dysfunction or perturbation in normal
feedback mechanisms relating to feeding behavior and energy
balance. The adaptive response or “thrifty gene” theory of obesity
explains how genes favoring the efficient use of energy store in
periods of feast followed by famine result in obesity in the foodrich or “obesogenic” environment of prosperous societies (9, 10).
This “thrifty gene” hypothesis has been the dominant theory of
the developmental origins of obesity and related chronic disease.
The “thrifty gene” hypothesis provides a potential explanation
for the dramatic rate of T2D and obesity prevalence in Pima
Indian population of Arizona relative to the genetically similar
Pima Indians in Mexico (11). However, there are only limited
experimental studies that have tested the adaptive-survival value
of an obese-prone genotype. Our ongoing research is based on
the JCR:LA-cp rodent model that expresses the corpulent (cp)
autosomal recessive trait (cp), a nonsense Tyr763Stop mutation
in the Ob-R gene, resulting in a total absence of functional
leptin receptors (12). Animals that are homozygous for the cp
trait (cp/cp) are obese-prone, hyperphagic, and develop features
of the MetS, similar to the metabolic aberrations observed in
the clinical setting (13). Animals that are heterozygous for the
cp trait (+/cp) or wild type (+/+) are lean-prone, have normal
food intake, and do not develop the MetS. To verify the adaptive response hypothesis that an obese-prone genotype confers
a survival advantage when challenged with dietary energy
restriction and food-seeking behavior induced activity, juvenile
Frontiers in Nutrition | www.frontiersin.org

CHARACTERIZATION OF THE ALTERED
IMMUNE FUNCTION IN OBESITY USING
THE JCR:LA-cp RAT MODEL: MODULATION
WITH AGE AND DIETARY FAT
Obesity is often recognized as a chronic inflammatory state with
altered immune responses, including T cell dysfunction (17–19).
The JCR:LA-cp rat model of the MetS shares altered immune
function, similar to that observed clinically in obese individuals
(17–19). The obese-prone rodent model has chronic low-grade
systemic inflammation (20–22) and, recently, has been shown
to have inflammation in the brain (23, 24). Our group has also
demonstrated significant alterations in the acquired immune
system of the obese-prone phenotype (19, 25–27). The altered
T cell function in the JCR:LA-cp rat appears to be dependent on
the age of the animal and length of time of exposure to a high-fat
diet. When a high-fat diet is introduced at 8 weeks of age and
fed for 3 weeks, the obese-prone rats have fewer splenocytes (an
indicator of the peripheral lymphopenia) compared to their leanprone counterparts (27). The obese-prone animals also have a
3
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higher proportion of macrophages, T-cells (primarily CD8+ and
CD4+) and CD4+CD25+ (T regulatory cells) (27). This inflammatory T cell response would contribute to the overall chronic
inflammation observed in these animals. When splenocytes from
the JCR:LA-cp rats are stimulated ex vivo with Concanavalin
A (ConA, polyclonal T cell mitogen), they produce the same
amount of IL-2 (proliferative cytokine) but have increased levels
of the inflammatory cytokine IL-6 (27). In mesenteric lymph
nodes (MLN), which are part of the gut-associated lymphoid
tissue and visceral adipose tissue, the obese-prone rats have a
lower proportion of T-cells (both CD4+ and CD8+ cells) and
fewer mature T cells (CD3+CD90+), with a higher proportion
of CD4+CD25+ (T regulatory cells) (27). Despite lower T cell
numbers, ex vivo, MLN from obese-prone rats produce higher
amounts of IL-2, IL-10, IFN-γ, and Tnf-α after stimulation with
Con A (27), suggestive of a highly reactive pro-inflammatory
state in the intestine. When a high-fat diet was fed for 3 weeks
to older JCR:LA-cp animals (aged 14 weeks), splenocytes had
a lower inflammatory response in IL-6 and IL-10 production
in the unstimulated condition. In stimulated conditions [with
ConA, lipopolysaccharide (LPS), or pokeweed], a lower production of IFN-γ and decreased IL-1β (LPS) and IL-10 (Con A) was
observed (25). This suggests, similar to the human condition, that
the animals have some degree of immunosuppression and which
would make them susceptible to infection. In splenocytes, there
was a greater number of CD4+ cells and fewer CD4+CD25+
cells, B cells, and macrophages in obese-prone animals. In MLN,
a greater production of IL-4 following Con A stimulation, and
IL-1β, IL-10, and IFN-γ after stimulation with LPS was observed
(26), again suggestive of intestinal inflammation or increased
exposure to antigens (perhaps microbiome) from the intestine.
In addition, there was a higher proportion of CD3+CD8+ cells
and a lower proportion of CD4+CD25+ in the obese-prone
animals (26), consistent with chronic inflammation. When a
high-fat diet is introduced at 3 weeks of age and fed for 13 weeks,
the obese-prone rats have a lower proportion of CD3+ cells
(both CD4+ and CD8+), a higher proportion of CD4+CD25+.
In addition, these animals have naive or less mature CD4+
cells and activated B cells in the spleen compared to lean-prone
control animals (20), which would leave the animals more prone
to infection. With the exception of IL-2 production, which did
not differ between obese- and lean-prone animals, the ex vivo
production of cytokines after stimulation was exacerbated in this
group compared to previous studies in older animals or fed for
shorter periods of time. After Con A stimulation, splenocytes
from obese-prone animals produced lower levels of IL-1β (43%),
IL-4 (53%), Tnf-γ (31%), and IFN-γ (31%), and twofold greater
IL-6 compared to lean-prone animals (20).
In summary, the obese-prone JCR:LA-cp rat displays an
immune dysfunction that is similar to that reported in obese
individuals (17–19, 28), which suggest lymphopenia and immunosuppression and abnormal inflammatory responses to immune
challenges. Differences in immune cell type and function are
observed in both the intestinal lymphoid tissue and peripheral
immune system suggesting that there is both systemic and intestinal involvement. Interestingly, we have learned that the altered
immune profile of the JCR:LA-cp rat is also modified by the age

Frontiers in Nutrition | www.frontiersin.org

and length of feeding period of a high-fat diet. Additionally, we
have also demonstrated that immune dysfunction in this model
can be improved by dietary supplementation with long-chain
polyunsaturated fatty acids (PUFA), including trans-vaccenic
acid (20, 27) and fish oil containing docosahexanoic and eicosapentanoic acid (25, 26).

INFLAMMATION, STROKE, AND
INFECTION IN OBESITY
We and others have contributed to the fact that high levels of circulating biomarkers of inflammation are present in the obese state
(29). We know that obese individuals are more likely to develop
other chronic inflammatory conditions, including certain forms
of cancer, diabetes, cardiovascular, and cerebrovascular disease.
Mechanisms by which obesity alters immune and inflammatory
responses and how these changes contribute to the development
of other diseases are still not clear.
Stroke is a major cause of morbidity and mortality, and the
incidence of an ischemic episode has been associated with peripheral and central immune dysfunction (30). Chronic systemic
inflammatory conditions, such as infections, atherosclerosis,
diabetes, and obesity are associated with increased risk of stroke,
suggesting that these conditions and associated inflammation
may contribute to the development of stroke (30). In this respect,
aged JCR:LA-cp rats have been shown to have increased brain
inflammation using PET imaging (23). Furthermore, patients
with multiple risk factors for stroke, in the absence of any
brain pathology, have also been shown to have increased brain
inflammation, and this may be associated with increased risk for
cerebral ischemia (23). Despite research efforts, there has been
a lack of translation of these findings from bench to bed side in
stroke patients. One reason for this may be the failure to consider
clinical comorbidities in experimental models of stroke. IL-1 is
altered peripherally in obesity and is also an important mediator
of ischemic brain injury (31). IL-1 receptor antagonist (IL-1Ra) is
protective against ischemic brain damage in healthy animals (31).
After cerebral ischemia, aged JCR:LA-cp rats showed increased
blood brain–barrier disruption and brain inflammation compared to their lean-prone counterparts, and this was reduced following systemic administration of IL-1Ra. IL-1Ra treatment was
also shown to significantly reduce the infarct volume (measured
by MRI) in obese-prone animals, further supporting IL-1Ra as a
lead candidate for the treatment of ischemic stroke (24).
Bacterial infections have been proposed to contribute to stroke
development and may worsen ischemic event outcomes (32).
In this setting, a sustained pulmonary infection (Streptococcus
pneumoniae isolate) induced in JCR:LA-cp was used to investigate the effect of infection on vascular and inflammatory
responses prior to and after cerebral ischemia (33). The results
showed that the pneumonia infection augmented atherosclerosis
and exacerbated ischemic brain injury via IL-1 and plateletmediated systemic inflammation pathways (33). Targeting these
mechanisms could be therapeutically useful to prevent infectioninduced thrombo-inflammatory responses that may predispose
individuals to ischemic vascular events and adversely affect stroke
outcomes.
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DEVELOPMENT OF DYSLIPIDEMIA
DURING OBESITY AND
HYPERINSULINEMIA: OVERPRODUCTION
OF LIPIDS BY THE INTESTINE AND
BIOACTIVE TRANS-FATTY ACIDS

lipid-lowering and insulin-sensitizing therapies for CVD and
diabetes-related dyslipidemia (44, 45). Activation of PPAR-α
can effectively reduce plasma hypertriglyceridemia possibly via
modulating fatty acid oxidation and energy homeostasis pathways. Upregulation of PPAR-γ activity has also been shown to
normalize insulin sensitivity, improve lipid metabolism, and the
clearance of lipoproteins, as well as restore vascular contractility
and endothelial function (46). We became interested in the fact
that a number of natural PPAR-α ligands exist among which
include long chain and PUFA (e.g., oleic acid, arachadonic acid,
eicosapentaenoic acid, and docosahexaenoic acid) (47, 48).
More specifically, conjugated linoleic acid (CLA) is another
naturally occurring agonist of the PPAR-α pathway, which has
been proposed to be a primary mechanism via which CLA elicits
pleiotropic effects (49, 50). It has now been recognized that aside
from being converted to c9,t11-CLA in vivo, its precursor vaccenic acid (VA) may also have independent bioactivity in regulating lipid metabolism. However, few studies have attempted to
explore the metabolic pathways that are potentially modulated
by VA. Using the obese JCR:LA-cp rat, we have offered a number
of contributions to better understand the potential role of VA
in activating and thereby regulating lipid metabolism (51, 52).
Most recently, our group has obtained data indicating that VA
is a potent PPAR-α and PPAR-γ agonist and strongly binds to
the ligand-binding domain of both receptors. In accordance, we
found a substantial elevation in energy expenditure during both
light and dark cycle in VA-supplemented obese JCR:LA-cp rats
(40, 53). The observed change in energy metabolism may partially
be accredited to enhanced citrate synthase activity (an indicator
of fatty acid oxidation) in liver and adipose tissue of VA/CLA-fed
obese rats. Our evidence implies an active involvement of these
nuclear receptors in regulating lipid metabolism, which is shared
by other bioactive fatty acids such as DHA and c9,t11-CLA. These
findings have been important in understanding the role of ruminant derived trans-fatty acids as a class, and how they differ from
pro-inflammatory industrial produced trans-fatty acids through
the partial hydrogenation of vegetable oils (54).
In addition to PUFA and ruminant trans-fatty acids, prebiotic
fibres have also been proposed to promote weight loss and lower
plasma lipids; yet, the mechanisms are not fully understood.
By using the JCR:LA-cp rat, Parnell and Reimer have demonstrated that a 10% dietary blend of prebiotic fibres (inulin and
oligofructose) can lower total cholesterol concentrations. The
dietary blend is thought stimulate cholesterol excretion in the
form of bile as well as reduce hepatic steatosis through a FAS
independent mechanism (55).

Intestinal Contribution to
Hypercholesterolemia and
Diabetic Dyslipidemia

One of the most significant advances that have occurred over
the last 5 years with respect to intestinal lipid metabolism is the
understanding of how the gut contributes to whole body cholesterol homeostasis (34). In particular, we now appreciate how
these intestinal-based mechanisms become dysfunctional under
conditions of obesity and insulin resistance. Using the JCR:LA-cp
rat model, we have shown that circulating hyperinsulinemia (as
is the case during conditions of MetS or prediabetes) can lead to
increased absorption of both lipid and sterol from intestine that
can, in turn, exacerbate dyslipidemia and CVD risk. Specifically,
we have demonstrated that insulin resistance results in a chronic
overproduction and excessive secretion of intestinal-derived
apoB48-containing chylomicron particles. This finding is consistent with studies from the JCR:LA-cp rat (35), the hamster (36),
and, more recently, humans (37).
Mechanisms responsible for the overproduction of intestinalderived lipoproteins have been reviewed elsewhere (38) but can
include stimulation by excess free fatty acids, manipulation of
both GLP-1 and GLP-2, increased circulating Tnf-alpha, increased
stability of apoB48, and the downregulation of enterocytic insulin
receptor (IR) substrate-1. Work from our own group utilizing the
JCR:LA-cp rat has also confirmed that this is likely multifactorial
resulting from; suppression of enterocytic Pparα (39), increased
SREBP-1 (40), decreased ABCG5/G8 (39), and increased phosphorylation of JNK (41). New emerging data also suggest that
increased enterocytic Tnfα may also contribute to increased apoB
per se (42). In addition, Parnell and Reimer have elegantly shown
that there is an increase in satiety hormone (proglucagon, PYY,
and ghrelin) mRNA expression in the JCR:LA-cp rat gut that may
potentially contribute to intestinal lipid overproduction (43).
Importantly, these observations provide valuable mechanistic
explanation for why those with the MetS and diabetes typically
have a unique lipoprotein phenotype. Left untreated, those with
obesity and early insulin resistance develop atherogenic dyslipidemia that renders a significantly increased CVD risk profile.
Other efforts from our laboratory have used the JCR:LA-cp rat
to better understand potential nutritional means to curb these
metabolic impairments.

ARTERIOGENESIS IS MEDIATED BY
microRNA IN THE CARDIOVASCULATURE
AND IS ASSOCIATED WITH INTESTINAL
LYMPHATIC LIPOPROTEINS IN THE
METABOLIC SYNDROME

Impact of Dietary Long-Chain Fatty
Acids, PUFA, and Ruminant Trans-Fatty
Acids to Lipoprotein Metabolism in the
JCR:LA-cp Rat

Coronary collateral growth (arteriogenesis) is an important
adaptive process in transient, repetitive coronary artery occlusion, and myocardial ischemia, which occurs in stable angina

Pharmaceutical compounds that activate peroxisome proliferator-activated receptor (PPAR)-α and PPAR-γ (e.g., fibrates and
thiazolidinedione, respectively) have been successful as potent
Frontiers in Nutrition | www.frontiersin.org
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pectoris. Well-developed collateral networks are associated with
lower incidence and severity of myocardial infarction (56).
In contrast to angiogenesis, which is characterized by new vessel
(capillary tube) formation, arteriogenesis is defined by remodeling and enlargement of small arterioles (with very low blood
flow) to connect with larger conducting arteries. This process
critically depends on both normal endothelial (57, 58) and vascular smooth muscle cell (VSMC) function (59). Arteriogenesis
has shown to be severely impaired in animal models exhibiting
endothelial dysfunction, including the Zucker obese pre-diabetic
(ZOF) rat (60) and the MetS obese-prone JCR:LA-cp rat (59, 61,
62). Human patients with impaired endothelial function and the
MetS also exhibit impaired arteriogenesis (63–65).
We have recently shown that microRNA (miR)-145 and miR21 are important regulators of arteriogenesis. miR-145 levels are
reduced in the JCR:LA-cp obese-prone rat compared to the leanprone metabolically normal animal, and when miR-145 levels
are upregulated in the obese-prone animal, the result is complete
restoration of coronary collateral growth (59). This effect was
mediated by conversion of the aberrant synthetic VSMC phenotype to the normal contractile VSMC phenotype in the obeseprone model (59). miR-21 levels were markedly increased in the
heart of obese-prone animals, shown to be positively correlated
with VSMC proliferation (66) and decreased apoptosis of neutrophils (66). Conversely, downregulation of miR-21 to levels found
in lean-prone animals resulted in significant collateral growth
recovery in obese-prone animals, associated with a decrease
in VSMC proliferation (66); concomitant with a restoration of
apoptosis of neutrophils (67). miR-21 is well accepted as a major
pro-survival and pro-proliferative miR. Moreover, elevated miR21 levels were shown to be positively correlated with: increased
expression of pro-proliferative markers (G1/S and G2/M cyclins
and cyclin-dependent kinases); low expression of “tumor suppressors” (p21, p27, and pRb); high expression of anti-apoptotic
Bcl-2/Bcl-2 dimers; low expression of pro-apoptotic Bcl-2/Bax
dimers (caspases 9 and 3); and decreased cytochrome c release
from the mitochondria. Collectively, this study established that
miR-21 can regulate neutrophil apoptosis and is a required
component for successful collateral enlargement.

metabolic turnover of HDL and the reverse cholesterol transport
system (71). These results suggest that altered enterocyte lipid
and lipoprotein metabolism and/or HDL-dependent lymphatic
cholesterol transport may be inter-related to the elevated cardiac
miR-21 levels observed in the obese-prone JCR:LA-cp model.

EARLY INTIMAL ATHEROGENESIS,
ARTERIAL LIPID RETENTION, AND NOVEL
THERAPEUTICAL TARGETS
Impact of Remnant Dyslipidemia to
Atherosclerotic Vascular Disease during
Obesity and Insulin Resistance

One of the major complications of obesity and T2D is the
dramatic increased risk for CVD [specifically, atherosclerotic
vascular disease (ASVD)], the reasons for which are multifactorial. We have been very interested in understanding the role that
chronic metabolic disease has in exacerbating dyslipidemia and
how this mechanistically translates into greater lipid deposition
within the arterial wall. Atherogenic cholesterol-dense lipoproteins (for example, low-density lipoprotein, LDL-C) are thought
to permeate both intact and/or damaged arterial endothelium,
become entrapped within the sub-endothelial space, and
accumulate, resulting in inflammation and atheroma (72, 73).
Although the literature documents a significant epidemiological
and/or genetic (i.e., GWAS) association between raised circulating fasting LDL-C and ASVD risk, a large proportion of subjects
diagnosed with CVD are either normolipidemic (normal levels
of LDL) or have substantial residual risk (74–76). These data
suggest that clinically, atheromata-associated cholesterol is
derived from alternate sources, including non-fasting remnant
lipid fractions as originally proposed by Zilversmit (77). Indeed,
the International Atherosclerosis Society has recognized nonfasting measurements of remnant cholesterol as a major target
in their “Global Recommendations for the Management of
Dyslipidemia” (78).
Interestingly, a series of recent publications authored by the
Copenhagen Heart Study group have provided evidence for a
major shift in the paradigm of atherogenesis (and potentially its
therapy), suggesting that remnant (non-fasting) cholesterol is a
major causative factor for ischemic heart disease (IHD) (79, 80).
Using the JCR:LA-cp rat, we have also collected a substantial
array of preclinical data showing that remnant lipoproteins carry
substantially more cholesterol (due to their size and enrichment) compared to other atherogenic fractions. Using wellestablished arterial perfusion methodology, we have conducted
comparative dual labeling lipoprotein experiments. Cy5-labeled
remnants were isolated, purified, and perfused simultaneously
with Cy3-labeled LDL (designed to expose equivalent LDLderived apoB100 and remnant-derived apoB48). We observed
a significantly greater number of LDL particles delivered to the
vessel (4.5 ± 1 × 10−9 µg/µm2 tissue) as compared to remnants
(0.48 ± 0.15 × 10−9 µg/µm2 tissue) (81). However, after extensive
washout (a further 60 min) with lipoprotein-free buffer (i.e.,
representing residual retention), we observed significantly
fewer (55% decrease) LDL particles remaining in the tissue

A Role for the Lymphatic Expression of
microRNA in Lipid Metabolism?

Interestingly, miR-21 expression was also significantly increased
in jejunal enterocytes isolated from obese-prone JCR:LA-cp rat.
The concentration of miR-21 in these animals was also increased
in intestinal lymph and in the high-density lipoprotein (HDL)
fraction isolated from the lymph (66). miR-21 levels in enterocytes
were examined because, in the obese-prone animal, the intestine
has overproduction of lipids associated with increased secretion
of chylomicrons (CM), and HDL is also found in the lymphatics isolated from the intestine (68). This intestinal secretion of
lipids contributes significantly to the lipid–lipoprotein content
of the lymphatics (68). Our results further indicated that 95% of
miRs in intestinal lymph was associated with the HDL fraction,
rather than the CM fraction (68). HDL has also been identified
as a major transporter of miRs in the circulation (69, 70). More
recently, the lymphatic system was revealed to be critical for the
Frontiers in Nutrition | www.frontiersin.org
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(2.9 ± 0.42 × 10−9 µg/µm2 “retention” vs. 4.5 ± 1 × 10−9 µg/µm2
“delivery,” p < 0.05). Additional studies have gone on to show
that there is an increased deposition of remnant lipoproteins in
arteries from JCR:LA-cp rats as demonstrated by arterial perfusion of equivalent numbers of particles. Mechanistically, we have
proposed that this phenomenon may be due to (a) dyslipoproteinemia and/or (b) perturbations in the vessel wall. Crossover
perfusion experiments have revealed that increased retention
of the number of remnant lipoproteins during insulin resistance
was due to differences in arterial vasculature and independent of
other factors effecting particle dysfunction per se.

Ischemic myocardial lesions constitute a critical end point
in CVD. Previous studies using the JCR:LA-cp rat strain have
demonstrated a correlation between the frequency of myocardial
lesions with hyperinsulinemia (92). Hearts isolated from JCR:LAcp rats treated with either EZ (−84%) or EZ + SV (−84%) have
displayed a significant reduction in the frequency of early stage
2 myocardial lesions or very recent ischemic lesions undergoing
scavenging and repair, characteristic for this strain at this age.

ESTABLISHING JCR:LA-cp RODENT RAT
AS A MODEL OF SPONTANEOUS LEFT
VENTRICULAR HEART DYSFUNCTION

Impact of Obesity and Insulin Resistance
on the Extracellular Matrix and Arterial
Remodeling

The JCR:LA-cp rat has previously been identified as a model that
also includes pathological complications of endothelial dysfunction and myocardial ischemia, in addition to other dysfunctional
complications consistent with the MetS (41, 92, 93). We have
recently demonstrated that JCR:LA-cp rats exhibit significant
cardiac dysfunction and present as a useful animal model of
spontaneous LV dysfunction (94). JCR:LA-cp rats were subjected
to Doppler echocardiography analysis (Vevo 770 Micro-Imaging
system). 2-D parasternal long- and short-axis images of the left
ventricle (LV) were obtained using a 25-MHz linear-array transducer and doppler probe in anatomical M-mode at the level of
papillary muscles at a sweep speed of 150 mm/s. We observed that
JCR:LA-cp rats exhibited distinct signs of cardiac dysfunction,
and that hearts exhibited a marked increase (~40%) in LV mass
vs. their lean counterparts. Echocardiographical analysis also
revealed that hearts from JCR:LA-cp rats had an increased early
(MV-E) filling velocity (~40%) and reduced late (MV-A) filling
(~15%) velocity compared to age-matched lean rats. We further
revealed that JCR:LA-cp rats had a restrictive filling pattern, shown
by a significantly shortened isovolume relaxation time (IVRT)
(~30% decrease). Finally, we found that JCR:LA-cp rats exhibited
progressive worsening of diastolic filling properties, with a 1.6-fold
increase in the ratio of early to late filling velocity (E/A).

Our group has also shown that intestinal-derived remnant
lipoproteins can colocalize with arterial biglycan in an insulindeficient model of type I diabetes ex vivo (82). Subsequently, we
have demonstrated, in the JCR:LA-cp rat, that in the prediabetic
milieu, aortic biglycan protein core content increases significantly
with age and correlates linearly with increasing hyperinsulinemia. We know that the expression of biglycan protein core has
been shown to be increased with fatty acids (83, 84), angiotensin
II (85), and transforming growth factor-β (TGF-β) (86, 87).
Consistent with this, obese JCR:LA-cp rats have been shown to
have elevated concentrations of TGF-β (88) and non-esterified
free fatty acids (51).

Arterial Retention of Remnant
Lipoproteins and Associated Cholesterol
Deposition in Response to Ezetimibe and
Simvastatin

Ezetimibe (EZ) is a pharmaceutical compound that selectively
reduces intestinal cholesterol absorption by inhibiting the
Niemann-pick C1-like 1 (NPC1L1) transporter (89) while
Simvastatin (SV) is a HMG-CoA reductase inhibitor. Using the
arterial perfusion approach in the JCR:LA-cp rat, we have shown
that EZ treatment can ameliorate the deposition of arterial remnants and associated cholesterol ex vivo (90). It is also intriguing,
that the addition of SV to EZ appeared to have an additional
benefit reducing arterial cholesterol deposition, suggesting a
synergism of independent modes of action.

THE FEMALE JCR:LA-cp RAT AS A MODEL
OF POLYCYSTIC OVARY SYNDROME
AND CARDIOMETABOLIC RISK
The JCR:LA-cp Rat as a Spontaneous
Model of PCOS

Polycystic ovary syndrome (PCOS) has become an increasing
public health concern given its association with menstrual
dysfunction, infertility, MetS, T2D, and CVD risk (95, 96). The
syndrome afflicts 5–18% of women in their reproductive years, in
adolescents to premenopausal women. PCOS is diagnosed by the
presence of clinical or biochemical hyperandrogenemia, menstrual irregularity, and/or polycystic ovaries (97). The incidence
of PCOS is twofold to threefold greater in overweight-obese adolescents and women and is coassociated with features of the MetS
including obesity, impaired insulin sensitivity, and dyslipidemia
predisposing women to increased risk of prematurely developing
T2D and CVD (96, 98, 99). Animal models of PCOS have been
used to further understand the role of androgens, in particular

Combination of Ezetimibe with
Simvastatin Improves Fasting and
Postprandial Lipids

A study by Bozzetto et al. reported that the combination of EZ
with SV in T2D subjects can beneficially impact both fasting and
postprandial triglyceride-rich lipoproteins (91). They found that
the addition of EZ to SV reduced the number of circulating CM
particles (apoB48) in the postprandial state, while also lowering
both fasting and postprandial chylomicron cholesterol (88).
Postprandial data from studies in JCR:LA-cp rats are consistent
with benefits of either EZ + SV therapy on both remnant particle
metabolism and corresponding cholesterol (81).
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testosterone, on the development of the metabolic aberrations in
this condition, and the features of these models have been previously reviewed (100, 101). These models have primarily used
testosterone to induce PCOS; however, the JCR:LA-cp rodent
model is the only model to spontaneously develop PCOS in conditions of the MetS (102). The significance of the JCR:LA-cp rat
in this context is the similarity to the human condition in which
the development of the PCOS phenotype is preceded by increased
adiposity and insulin resistance. Interestingly, we have known, for
some time, that female homozygous JCR:LA-cp rats are infertile
but have only recently begun to appreciate the metabolic impactions. In humans, females that carry a predisposition for insulin
resistance due to family history often see a clinical presentation
that antagonizes endocrine–reproductive dysfunction, a feature
that is also observed in female JCR:LA-cp rats (96, 103, 104).

Hepatic and intestinal lipogenic gene expression showed that
flutamide may lower hepatic SREBP-1, LDLR, and HMGCR in
PCOS-prone animals (110). Interestingly, PCOS-prone animals
have reduced IR, MAPK1, AKT2, and PTPN1 mRNA expression in the intestine, but not the liver. However, flutamide and
metformin treatment appeared to favor hepatic upregulation of
the IR mRNA, as well as MAPK1 and protein kinase B (AKT2);
however, in the intestine, MAPK1 was downregulated, and no
effect on AKT2 mRNA expression was observed in PCOS-prone
animals. Overall, these findings indicate that lipogenic and insulin signaling gene expression is altered in PCOS-prone animals
compared to lean-prone controls. Effects of AR inhibition and
insulin-sensitizing treatments appear to modify these pathways
in association with improvements in plasma and intestinal secretion of lipids (110).

Cardiometabolic Risk, Dyslipidemia, and
the Hypothalamic–Pituitary–Gonadal Axis

Energy Restriction and Exercise
Intervention in the Female JCR:LA-cp Rat

The pathogenesis of PCOS is linked to altered hypothalamic–
pituitary–gonadal axis function and perturbed insulin and
testosterone metabolism (105, 106). One of the major areas of
research in the PCOS-prone JCR:LA-cp rodent model is understanding the distinct mechanisms of androgens and insulin in
the cardiometabolic manifestations, particularly dyslipidemia
and CVD risk (102, 107, 108). Dyslipidemia occurs in greater
than 70% of PCOS patients and is positively correlated with
increasing quartile of plasma hyperandrogenemia (97, 99). We
have characterized the dyslipidemic profile of the PCOS-prone
JCR:LA-cp rodent model, which has markedly elevated fasting
and non-fasting plasma TG, total cholesterol (TC), apoB48, and
apoB100 (markers of intestinal CM and hepatic very low-density
lipoprotein and low-density lipoproteins, respectively) compared
to control animals (35, 104). PCOS-prone animals have twofold
the intestinal triglyceride, cholesterol, and apoB48 secretion in
the fasted state compared to their lean-prone control counterparts, and this is associated with increased mRNA expression of
SREBP-2, LDLR, and apoB (102, 107). When given dietary lipid,
this elevated CM lipoprotein particle (apoB48) and lipid (cholesterol and TG) secretion is further exacerbated (107). We have
further shown, in this model, that plasma testosterone and insulin
are positively correlated with fasting and non-fasting plasma TG
and apoB48, consistent with the role of these lipogenic mediators
in the development of dyslipidemia in PCOS, insulin resistance,
and obesity (106, 107, 109).
Intervention with flutamide, an androgen receptor (AR)
inhibitor, has confirmed that testosterone action via the AR mediates apoB-hyperlipoproteinemia and hypertriglyceridemia, and
this appears to be independent of effects on insulin (110). Fasting
plasma apoB100, apoB48, and TG concentrations were lowered by
25–50% in animals treated with flutamide. Flutamide–metformin
combination treatment similarly lowered these parameters;
however, metformin treatment alone had no effect on fasting
plasma lipids, indicating a predominant effect of the AR inhibitor
to mediate lowering of plasma lipids. Additionally, the intestinal
secretion of TG, cholesterol, and the cholesterol/apoB48 and
TG/apoB48 (a marker of lipid per CM particle secreted from the
intestine) were markedly reduced following flutamide treatment.
Frontiers in Nutrition | www.frontiersin.org

In the PCOS-prone model, we have shown that energy restriction
and voluntary exercise intervention (4 h/day) at an early life stage
can significantly attenuate reproductive and cardiometabolic
aberrations (111). The combination of diet and exercise was
shown to lower total body weight gain and body fat mass by
30% in PCOS-prone animals. Consistent with our ongoing
studies on dietary energy restriction and food-seeking-induced
exercise (112, 113), we have also found that energy restriction
independently induces food-seeking behavior related activity in
the PCOS-prone animal, favoring an increase in energy expenditure. In terms of cardiometabolic risk, the combination of energy
restriction and exercise decreased fasting plasma TG and apoB48
in PCOS-prone animals. In addition, the combination of exercise
and dietary energy restriction increased serum hormone-binding
globulin and free androgen index, and normalized mRNA
expression of hypothalamic CART and Kisspeptin. Collectively,
these findings were associated with improvements in follicular
morphology and estrus cyclicity. In similar exercise conditions,
we have shown that the addition of metformin–flutamide treatment lowers total body weight and body fat-pad weight and tends
to lower fasting plasma lipids. Interestingly, a combination of
both metformin and flutamide treatment, in addition to exercise
further reduces free Testosterone and improves estrus cyclicity
compared to exercise alone (113).
The findings of this work have revealed voluntary exercise has
modest effects on cardiometabolic risk factors, and the inclusion
of medications that specifically target insulin resistance and
dyslipidemia are required to modulate these risk factors in this
obese PCOS-prone model. These results have also highlighted
the necessity for early intervention with combinations of lifestyle
and/or dietary pharmaceutical medication to modulate the hypothalamic–pituitary–ovary axis.

IMPACT OF JCR:LA-cp RAT MODEL TO
TRANSLATIONAL OUTCOMES FOR OBESITY
One measure of impact for the appropriateness of animal
models to research is the usefulness of preclinical outcomes for
8
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clinical translation. Perhaps the most successful application of
the JCR:LA-cp rat model has been its suitability to study the
progression of metabolic disease from initial stages of overnutrition (without the need for dedicated high caloric diets),
resulting in the development of insulin resistance through to
the phenotypic complications of hyperinsulinemia and hallmark
conditions of the MetS. Many of the advances discussed in this
review have made an impact to a better understanding of the
human clinical condition. One such example is the revelation of
how the intestine integrates and coordinates whole body lipid
metabolism more prominently than previously appreciated
(114). The discovery that the intestine will contribute to dyslipidemia through unregulated overproduction of lipids has been
confirmed clinically in those with insulin resistance and T2D
(115, 116). This in turn has provided a new platform for modes
of action of different classes of pharmaceutical compounds;
including intestinal cholesterol transporter inhibition and incretion blockade. At the same time, the understanding of remnant
cholesterol metabolism and how this relates to early conditions
of childhood obesity has also come to the fore in the context of
potential subclinical risk of CVD (117, 118).
The vision for this research sector will be to continue to strive
for ways to aid the younger generation to become more aware
of the comorbidities of obesity in childhood, and how they will

progress into adulthood. In order to achieve this, we will have
to target methodologies that identify metabolic risk of obesity
in the younger generation that can have usefulness in the clinic
and beyond.
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